Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: An analysis of 497 patients

Transfusion

Volumn 37, Issue 9, 1997, Pages 896-903

  Weaver, C H ^a   Schwartzberg, L S ^a   Birch, R ^a   Greco, F A ^a,b   Rhinehart, S ^a,c   Hainsworth, J ^a,b   Beeker, T ^a,d   Price, H ^a,e   Geier, L ^a,f   Foster, J ^a,g   West, J ^a,h   Hazelton, B ^a   Buckner, C D ^a,i  

^a Response Oncology Inc   (United States)

^b Response Oncology Inc   (United States)

^c Fort Wayne Impact Center   (United States)

^d Mobile Impact Center   (United States)

^e Response Oncology Inc   (United States)

^f Response Oncology Inc   (United States)

^g Response Oncology Inc   (United States)

^h Response Oncology Inc   (United States)

ⁱ Response Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; APHERESIS; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CRYOPRESERVATION; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030809788     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1997.37997454014.x     Document Type: Article

References (27)

1. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-55.
2. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9.
3. Schwartzberg L, Birch R, Blanco R, et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993;11:369-74.
4. Schwartzberg L, Birch R, Hazelton B, et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992;1:317-27.
5. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-94.
6. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3970-8.
7. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-4.
8. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;2:580-5.
9. Bensinger WI, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993;81:3158-63.
10. Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte-colony stimulating factor. Blood 1993;82:1981-4.
11. Shepherd KM, Charles P, Sage RE, et al. Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 1991;13:25-32.
12. Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992;9:11-7.
13. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
14. Cox DR. Regression models and life-tables. J R Stat Soc 1972;(Series 6)34:187-202.
15. Janssen WE, Hiemenz J, Zorsky PE, et al. Mobilization of peripheral blood stem cells: comparing cyclophosphamide and growth factor based regimens. Prog Clin Biol Res 1994;389:429-39.
16. Brice P, Divine M, Marolleau JP, et al. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas. Bone Marrow Transplant 1994;14:51-5.
17. Pierelli L, Iacone A, Quaglietta AM, et al. Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicentre retrospective study. Br J Haematol 1994;86:70-5.
18. Hohaus S, Goldschmidt H, Ehrhardt R, Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 1993;21:508-14.
19. Koppler H, Pfluger KH, Havemann K. Hematopoietic reconstitution after high-dose chemotherapy and autologous nonfrozen bone marrow rescue. Ann Hematol 1991;63:253-8.
20. Mick R, Williams SF, Bitran JD. Patients at increased risk for late engraftment after transplantation: a novel method for their identification. Bone Marrow Transplant 1990;6:185-91.
21. Rabinowe SN, Neuberg D, Bierman PJ, et al. Long term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993;81:1903-8.
22. Taylor PR, Jackson GH, Lennard AL, et al. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group. Br J Cancer 1993;67:383-7.
23. Elliott C, Samson DM, Armitage S, et al. When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 1996;14:970-3.
24. Weaver CH, Potz J, Redmond J, et al. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ content. Bone Marrow Transplant 1997;19:1103-10.
25. Weaver CH, Hazelton B, Palmer PA, et al. A randomized dose finding study of filgrastim for mobilization of peripheral blood progenitor cells (PBPCs) (abstract). Proc Am Soc Clin Oncol 1996;15:341.
26. Dercksen MW, Gerritsen WR, Rodenhuis S, et al. Expression of adhesion molecules on CD34+ Cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 1995;85:3313-9.
27. Brugger W, Heimfeld S, Berenson R, et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995;333:283-7.